Xenon Pharmaceuticals Inc. (XENE)
| Market Cap | 3.85B +36.0% |
| Revenue (ttm) | n/a |
| Net Income | -409.20M |
| EPS | -4.73 |
| Shares Out | 96.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,948,749 |
| Open | 44.02 |
| Previous Close | 57.35 |
| Day's Range | 39.08 - 44.85 |
| 52-Week Range | 35.97 - 72.66 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 80.57 (+102.69%) |
| Earnings Date | Nov 2, 2026 |
About XENE
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price target is $80.57, which is an increase of 102.69% from the latest price.
News
Xenon Pharmaceuticals falls -28.9%
Xenon Pharmaceuticals (XENE) is down -28.9%, or -$16.60 to $40.75.
Xenon Pharmaceuticals falls -29.8%
Xenon Pharmaceuticals (XENE) is down -29.8%, or -$17.08 to $40.27.
Xenon Pharmaceuticals price target lowered to $70 from $81 at RBC Capital
RBC Capital lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $70 from $81 and keeps an Outperform rating on the shares. The firm cites the company having paused…
Xenon Pharmaceuticals price target lowered to $55 from $71 at Wedbush
Wedbush lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $55 from $71 and keeps an Outperform rating on the shares. The firm notes the company Xenon disclosed a…
Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.'
Xenon Pharmaceuticals price target lowered to $60 from $78 at Needham
Needham lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $60 from $78 and keeps a Buy rating on the shares. The firm cites the company having paused the…
Xenon Pharmaceuticals price target lowered to $90 from $97 at Baird
Baird lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $90 from $97 and keeps an Outperform rating on the shares.
Xenon Pharmaceuticals price target lowered to $64 from $69 at Wells Fargo
Wells Fargo analyst Benjamin Burnett lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $64 from $69 and keeps an Overweight rating on the shares. The firm notes shares…
Citi views Xenon study pause as positive for Biohaven
Citi analyst Samantha Semenkow views Xenon Pharmaceuticals’ (XENE) voluntarily pause in new enrollment for its ongoing trials for major depressive disorder and bipolar depression as favorable for Bioh...
Xenon Pharmaceuticals downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst David Hoang downgraded Xenon Pharmaceuticals (XENE) to Hold from Buy with a price target of $46, down from $90. The company reported neuropsychiatric adverse events in its…
Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns
Xenon Pharmaceuticals on Thursday said it has temporarily paused enrolling new patients in clinical studies testing its experimental drug for major depression and bipolar disorder, following reports...
Xenon Pharmaceuticals Transcript: FDA announcement
Azetukalner's NDA for focal seizures was submitted to the FDA, supported by strong efficacy and safety data from pivotal trials. Enrollment in psychiatry studies is temporarily paused to adjust dosing after rare, mostly mild neuropsychiatric events, with top-line MDD results expected in Q1 2027.
Xenon Pharmaceuticals Press release: FDA announcement
Xenon Pharmaceuticals issued a press release on September 17, 2026, disclosing material business information to investors.
Xenon sinks after pausing depression study enrollment
Shares of Xenon Pharmaceuticals (XENE) are falling after the company said it implemented a voluntary pause on enrollment for new patients in its ongoing clinical studies in major depressive disorder…
Xenon Pharmaceuticals submits azetukalner NDA to FDA
Xenon Pharmaceuticals (XENE) announced it has submitted a new drug application, or NDA, for azetukalner in focal seizures, or FS, to the FDA. The NDA submission is based on positive…
Xenon Pharmaceuticals pauses enrollment for MDD, BPD studies
In addition, the company announced that it has implemented a voluntary pause on enrollment for new patients in its ongoing clinical studies in major depressive disorder, or MDD, and bipolar…
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
VANCOUVER, BC and BOSTON, MA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical devel...
Xenon Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Azetukalner is nearing NDA filing for focal onset seizures, with strong efficacy across four doses and plans for premium pricing. Launch will focus on epileptologists, expanding to general neurologists, and leverage a specialty distribution model. Pipeline includes neuropsychiatry and pain assets, with global regulatory and label expansion strategies underway.
Xenon to Present at Wells Fargo Healthcare Conference
VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical devel...
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical develo...
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical develo...
Xenon Pharmaceuticals price target lowered to $81 from $82 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $81 from $82 and keeps an Outperform rating on the shares.
Xenon Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 revenue grew 3% year-over-year (excluding non-recurring items), driven by strong consumables growth and exceptional demand for the new Atera platform. Instrument revenue declined as customers awaited Atera, but full-year guidance was raised on robust order flow and margin expansion.
Xenon Pharmaceuticals Earnings release: Q2 2026
Xenon Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Xenon Pharmaceuticals Quarterly report: Q2 2026
Xenon Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.